

Cloning and Expression of Gumboro VP2 Antigen in *Aspergillus niger*

Mohammad Azizi<sup>1,2</sup>, Bagher Yakhchali<sup>2</sup>, Abdolreza Ghamarian<sup>1</sup>, Somayeh Enayati<sup>1</sup>, Mahvash Khodabandeh<sup>2</sup>, and Vahid Khalaj<sup>1\*</sup>

1. Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

2. Industrial and Environmental Biotechnology Department, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

## Abstract

**Background:** Infectious Bursal Disease Virus (IBDV) causes a highly immunosuppressive disease in chickens and is a pathogen of major economic importance to the poultry industry worldwide. The VP2 protein is the major host-protective immunogen of IBDV and has been considered as a potential subunit vaccine against the disease. VP2 coding sequence was cloned in an inducible fungal vector and the protein was expressed in *Aspergillus niger* (*A. niger*).

**Methods:** Aiming at a high level of expression, a multicopy AMA1-pyrG-based episomal construct driven by a strong inducible promoter, *glaA*, was prepared and used in transformation of *A. niger pyrG*<sup>-</sup> protoplasts. SDS-PAGE and western blot analysis was carried out to confirm the expression of the protein.

**Results:** A number of *pyrG*<sup>+</sup> positive transformants were isolated and the presence of expression cassette was confirmed. Western blot analysis of one of these recombinant strains using monospecific anti-VP2 antibodies demonstrated the successful expression of the protein. The recombinant protein was also detected by serum obtained from immunized chicken.

**Conclusion:** In the present study, we have generated a recombinant *A. niger* strain expressing VP2 protein intracellularly. This recombinant strain of *A. niger* may have potential applications in oral vaccination against IBDV in poultry industry.

*Avicenna J Med Biotech* 2013; 5(1): 35-41

**Keywords:** *Aspergillus niger*, Recombinant proteins, VP2 protein

## Introduction

Infectious Bursal Disease Virus (IBDV) belongs to the family of Birnaviridae, which consists of naked viruses characterized by a bi-segmented, double strand RNA genome and is the causative agent of a highly infectious disease affecting young chickens (Gumbro disease)<sup>1</sup>. Current vaccination methods against IBDV are based on individual subcutaneous or intramuscular injection of inactivated or attenuated IBDV into birds. However, other administration routes such as ocular, nasal, oral or spraying are also common<sup>2</sup>.

VP2 and VP3 are the major structural proteins of the viral capsid which form 51 and 40% of the total proteins, respectively<sup>3</sup>. The VP2 protein with a molecular weight of ~42 kDa has been identified as the major host-protective immunogen of IBDV and contains main epitopes responsible for eliciting neutralizing antibodies<sup>4,5</sup>.

Several studies have documented the efficient induction of protective immune response against IBDV following administration of recombinant VP2. For example, feeding broilers

with VP2 expressing transgenic plants like rice seeds or *Arabidopsis thaliana* resulted in an antibody response against this protein<sup>6,7</sup>. These examples along with few other studies support the idea that direct feeding of chicks with engineered hosts may be considered as a potential oral vaccination method<sup>8,9</sup>.

Filamentous fungi, especially *Aspergillus* spp., are attractive production hosts for a wide variety of enzymes and metabolites. The ability to secrete high amount of bioactive proteins, GRAS (Generally Regarded As Safe) status, rapid growth on inexpensive media, high level of biomass production and well-defined genetic manipulation techniques are main advantages for the industrial application of these organisms<sup>10,11</sup>. For instance, the industrial strains of Aspergilli including *Aspergillus niger*, *Aspergillus awamori* and *Aspergillus aculeatus* have been successfully used in cost-effective production of various products in food and beverage, animal feed and paper-and-pulp industries<sup>12,13</sup>. Furthermore, there are several reports on the application of *Aspergillus* biomass or culture extracts as prebiotic in poultry industry and various products like Fermacto® (<http://www.pro-ag.com>) are available<sup>14</sup>.

Heterologous genes can be introduced to the fungal hosts via plasmids. Upon the integration of expression construct, various levels of the gene product can be expressed<sup>15</sup>. Despite the lack of natural plasmids in filamentous fungi, an autonomous maintenance *Aspergillus* (AMA1)-based plasmid has been developed for the episomal expression of gene constructs in *Aspergillus* spp<sup>16,17</sup>. The high frequency of transformation and relatively high copy number of plasmids in the nuclei facilitate a high level of expression<sup>18</sup>.

Here, we have used an AMA1-based episomal construct to express VP2 protein of IBD virus in *A. niger*. The recombinant protein was reactive to commercial anti-VP2 monoclonal antibodies and serum from vaccinated chickens.

## Materials and Methods

### Strains, plasmids and culture conditions

*A. niger* AB4.1, a *pyrG* derivative of *A. niger* N402<sup>19</sup>, was used in expression experiments. *E. coli* Top 10 (Invitrogen) cells were used in DNA recombinant procedures. Plasmid pGEM-glaA comprising *A. awamori* glaA promoter and glaA termination signal was used for the preparation of intermediate expression construct. Plasmid pRG3-AMA1-NotI containing *pyrG* gene as a fungal selection marker was used for the preparation of final expression cassette.

Fungal strains were grown and kept on SAB agar or SAB agar medium supplemented with uridine and uracil (UU). Modified Vogel's medium<sup>20</sup> containing 1% w/v maltodextrin as the sole carbon source was used in expression analysis.

### Construction of expression vector

The VP2 encoding sequence was cut from a previously prepared pPICZα-VP2 plasmid using *HindIII* and *XbaI* enzymes and cloned into *HindIII/XbaI* site of pGEM-glaA. To establish the correct reading frame, the resulting plasmid was digested with *XhoI* and then religated. This plasmid was called pglaA-VP2.2. To prepare the final construct, pAMA\_VP2, a 3 kb *NotI*- fragment of pglaA-Vp2 containing the glaA promoter, VP2 coding sequence and glaA termination signal was cut and cloned into *NotI* site of pRG3-AMA1 (Figure 1).

### Fungal transformation

*A. niger* AB4.1 cultures were grown for 20 hr in SAB-UU broth and protoplasts were prepared by gentle agitation of mycelia in a 5% (w/v) Glucanex (Novozymes, Switzerland) solution for 2 hr at 30°C. Transformation with pAMA-VP2 plasmid was mediated by poly ethylene glycol as described before<sup>21</sup>. Positive transformants were selected on Vogel's minimal medium lacking Uridin and Uralic.

### Phenotypic analysis of the strains

For phenotypic analysis of VP2 transformant strain and the wild type strain (*A. ni*




Figure 1. A) Schematic representation of expression cassette construction. Vp2 final fragment was cloned into *NotI* site of pRG3-AMA1; B) Restriction analysis of pAMA\_vp2. M: Size marker. Lane 2: Undigested pRG3-AMA1-NotI (plasmid backbone). Lane 3: *NotI* linearized pRG3-AMA1-NotI (~ 10 kb). Lane 3: undigested pAMA\_vp2. Lane 4: *NotI* digested pAMA\_vp2. The backbone plasmid (~ 10 kb) and the glaA-VP2 fragment (~ 3kb) are present

*ger* AB4.1 transformed with the empty pRG3-AMA1 plasmid), radial growth rates were determined by cultivation of  $10^4$  fresh spores from each strain on the center of SAB or modified Vogel's agar plates at  $30^\circ\text{C}$ ,  $37^\circ\text{C}$  and  $42^\circ\text{C}$  followed by serial measurement of

colonies' diameter for 5 days. Germination studies of wild type and VP2 transformant spores were carried out by incubation of fresh spores ( $10^4/\text{ml}$ ) in SAB or liquid minimal medium up to 8 hr in  $37^\circ\text{C}$ . The number of germinated spores was counted in 2 hr intervals (triplicate experiments) and the percentage of germinated spores was calculated.

### Expression analysis of vp2 in *A. niger*

A positive VP2 transformant was grown in 50 ml of inducing medium containing maltodextrin 1% (w/v) as the sole carbon source. The total fungal biomass was harvested after 24 and 48 hr of growth and then ground in liquid nitrogen. The resulting fine powder was re-suspended in a buffer containing 100 mM Tris-HCl pH=7.5 and 40  $\mu\text{l}/\text{ml}$  protease inhibitor cocktail. The suspension was incubated on ice for 30 min and then centrifuged for 15 min at 4000 rpm. The resulting supernatant for each time point was collected and subjected to immunoblot analysis.

For immunoblot analysis, aliquots of the protein samples (30  $\mu\text{g}$ ) were loaded on 12% SDS-PAGE and the protein bands were electro-transferred to a nitrocellulose membrane. Immunodetection of VP2 in Western blot analysis was carried out using both mono-specific antiVP2 antibodies (IBDV92 and IBDV67, HyTest, Finland) and polyclonal serum obtained from immunized chickens. The VP2 signal on nitrocellulose membrane was detected by ECL plus kit (Amersham, USA) or routine DAB staining.

## Results

### Construction of vp2 expression cassette

The expression construct was prepared in order to provide a high level of cytosolic expression of VP2 in *A. niger*. The VP2 gene segment with the size of 1355 bp was cut from an intermediate plasmid, pPICZ $\alpha$ -vp2, and successfully cloned into HindIII/XbaI digest of pGEM-glaA. As it is shown in figure 1 (A and B), the final expression plasmid was prepared by insertion of the *NotI* fragment of pglA-VP2.2 into *NotI* site of pRG3-AMA1

plasmid. Restriction analysis and DNA sequencing of pAMA-vp2 plasmid confirmed the correct cloning procedures (data not shown).

#### Transformation of *A. niger* AB4.1 strain

*A. niger* AB4.1 protoplasts were transformed with pAMA-vp2 plasmid. Several hundred *pyrG*<sup>+</sup> transformants were obtained from a single reaction (3  $\mu$ g plasmid). These transformants exhibited normal phenotype in minimal medium. A positive transformant was selected for further analysis.

To confirm that the expression cassette is present in this *pyrG*<sup>+</sup> transformant, Plasmid DNA was extracted from this transformant and subjected to restriction mapping. The results confirmed that the isolated plasmid is intact and identical to original plasmid, pAMA-vp2 (data not shown).

The colonies radial extension rates ( $K_r$ ,  $\mu$ m d<sup>-1</sup>) were determined as described earlier. The  $K_r$  value for VP2 transformant was  $73 \pm 5 \mu$ m h<sup>-1</sup> and for the wild type strain was  $76 \pm 4 \mu$ m h<sup>-1</sup> at 30 °C in SAB agar medium. Comparison of radial growth means using the t-test did not show a significant difference between the growth rates of these two strains ( $p < 0.05$ ). Similarly, no significant difference was observed between the VP2 positive transformant and the wild type when grown on modified Vogel's medium using different carbon sources including glucose and maltodextrin and different nitrogen sources like ammonium sulphate and peptone, or on complete medium at various temperatures (data not shown).

Germination studies of wild type and VP2 positive spores confirmed a similar pattern of germination type and the frequency of germinated spores. In SAB medium 65-70% of wild type or VP2 transformant spores were germinated after 4 hr incubation at 37°C, while the same percentage of germination in modified Vogel's medium was achieved after 8 hr.

#### Expression analysis of VP2

Expression of recombinant VP2 was induced by cultivation of transformant spores in induction medium as described earlier. Fol-




Figure 2. Western blot analysis on *A. niger* cell lysates using anti-VP2 antibodies. A) Detection of VP2 using polyclonal serum obtained from the immunized chickens. Lane 1: wild type strain; lane 2: vp2 transformant 24 hr sample; lane 3: vp2 transformant 48 hr sample; B) Detection of VP2 using anti-vp2 monoclonal antibody. Lanes' order is the same as A

lowing induction, 24 and 48 hr samples were taken and the lysates of both transformant and wild type strains were analyzed by SDS-PAGE. In Western blot analysis, a protein of ~42 kDa was reactive to anti-VP2 monoclonal antibodies and a positive serum obtained from immunized chickens (Figure 2A and B).

Densitometry analysis on SDS-PAGE gels demonstrated that the recombinant VP2 represents ~5% of total cell lyaste protein. This was equal to 0.23 mg/g of total biomass.

#### Discussion

Current vaccination methods against IBDV using inactivated or attenuated virus are associated with some disadvantages including high costs, poor efficiency and emergence of new variants<sup>7</sup>. Because of these limitations, attempts have been made to develop new sub-unit vaccines with fewer side effects. VP2 as the most important host protective immunogen of IBDV has been the focus of several studies. Despite the successful expression of VP2 in various eukaryotic systems, the purification of the recombinant protein is required<sup>22</sup>. Wu *et al* have examined the capability of VP2 expressing transgenic rice seeds in oral immunization of SPF chickens against IBDV.



Their results demonstrated that chickens can be immunized by direct feeding on the transgenic seeds, indicating the safe passage of antigen through the chicken GI tract <sup>7</sup>.

*Aspergillus* species, particularly *A. niger* and *A. oryzae* are employed in many commercial processes as protein production hosts. Different expression systems have been developed to improve production yields of recombinant proteins in these industrial hosts <sup>15</sup>. Moreover, as fermentation techniques are also well developed for these fungi, they can be grown in large quantities in inexpensive media <sup>23</sup>.

Here, we have used an episomal plasmid to express VP2 antigen in *A. niger*. Self replicating AMA1-based constructs are present at ca. 10 copies per nucleus and the level of expression of target gene is proportional to the copy number <sup>18</sup>. The promoter region was selected from the highly expressed glucoamylase A (glaA) gene to direct a high level of VP2 production. This promoter has already been used for the successful expression of both homologous and heterologous proteins <sup>24</sup>. Unlike the high levels of homologous protein production in *Aspergillus*, the heterologous protein production has been associated with low efficiency and generally the yields do not exceed few milligrams per liter without further optimizations <sup>25</sup>. In the present study, the data obtained from a densitometry analysis showed that the initial levels of cytosolic recombinant VP2 is around 5% of total cell lysate proteins. Other investigators have reported similar yields in cytosolic expression of heterologous proteins, ranging from 1% to 10% of total soluble proteins <sup>26,27</sup>.

VP2 protein is hydrophobic and an appropriate host is needed for its efficient expression <sup>28,29</sup>. Our results showed that *A. niger* is a suitable host for this purpose. The positive signal in western blot analysis of biomass crude extract using the immunized serum shows that the protein can be recognized by natural antibodies against IBDV indicating that the conformation of the recombinant protein is likely correct. To prove the antigenicity

of the recombinant VP2 protein, direct feeding of SPF broilers with fungal biomass followed by serum analysis for detection of anti-VP2 antibodies is required. Our preliminary data with non-SPF chickens have shown that the feeding of chickens with the recombinant fungus prevents the maternal antibodies to decline (unpublished data).

As our final goal was to feed chickens by whole fungal biomass, no secretory signal sequence was added to the final construct, leading to the production of the target protein in cytosolic form. The oral administration of vaccines has some advantages over other routes. Oral vaccines are more convenient, cost effective, easy boosting, and can be applied in large scale vaccination programs <sup>30,31</sup>. Comparing the transgenic plants, the cultivation of *A. niger* is more convenient and a large amount of biomass can be obtained in a short period. Cultivation of transgenic rice in the field or controlled green houses needs additional biosafety measures and large amount of spending, respectively. Furthermore, several studies have shown that *Aspergillus* meals (AM) can be used as a prebiotic in poultry industry. The benefits of AM include maturation of broiler GI tract, changing intestinal flora through the proliferation of useful bacteria, enhancement of resistance to pathogenic microorganisms and stimulation of growth by improving absorption of the feed ingredients <sup>32,33</sup>.

## Conclusion

Here we have shown that filamentous fungus *A. niger* can be used as a suitable host for the production of VP2 protein of IBDV. This recombinant host is able to produce VP2 protein in cytosolic form. The recombinant protein was detected by antiVP2 specific antibodies and serum obtained from immunized chickens.

## Acknowledgement

Part of this research has been sponsored by the Pasteur institute of Iran through a grant awarded to VK.

## References

1. Azad AA, Barrett SA, Fahey KJ. The characterization and molecular cloning of the double-stranded RNA genome of an Australian strain of infectious bursal disease virus. *Virology* 1985;143(1):35-44.
2. International Office of Epizootics (IOE), Biological Standards Commission. Infectious bursal disease (Gumboro disease). In: Commission OBS, ed. Manual of diagnostic tests and vaccines for terrestrial animals: mammals, birds and bees. Paris: OIE; 2008, 549-565.
3. Mundt E, Beyer J, Muller H. Identification of a novel viral protein in infectious bursal disease virus-infected cells. *J Gen Virol* 1995;76(Pt 2):437-443.
4. Berg TP. Acute infectious bursal disease in poultry: a review. *Avian Pathol* 2000;29(3):175-194.
5. Berg TP, Gonze M, Morales D, Meulemans G. Acute infectious bursal disease in poultry: Immunological and molecular basis of antigenicity of a highly virulent strain. *Avian Pathol* 1996;25(4):751-768.
6. Wu H, Singh NK, Locy RD, Scissum-Gunn K, Giambrone JJ. Expression of immunogenic VP2 protein of infectious bursal disease virus in *Arabidopsis thaliana*. *Biotechnol Lett* 2004;26(10):787-792.
7. Wu J, Yu L, Li L, Hu J, Zhou J, Zhou X. Oral immunization with transgenic rice seeds expressing VP2 protein of infectious bursal disease virus induces protective immune responses in chickens. *Plant Biotechnol J* 2007;5(5):570-578.
8. Li L, Fang WH, Fan YJ, Xu J, Fang L, Li JR, et al. Expression of the infectious bursal disease virus polyprotein in Vero cells using attenuated *Salmonella typhimurium* as transgenic carrier. *Sheng Wu Gong Cheng Xue Bao* 2004;20(3):437-440.
9. Mahmood MS, Hussain I, Siddique M, Akhtar M, Ali S. DNA vaccination with VP2 gene of very virulent infectious bursal disease virus (vvIBDV) delivered by transgenic *E. coli* DH5alpha given orally confers protective immune responses in chickens. *Vaccine* 2007;25(44):7629-7635.
10. Punt PJ, van Biezen N, Conesa A, Albers A, Magnus J, van den Hondel C. Filamentous fungi as cell factories for heterologous protein production. *Trends Biotechnol* 2002;20(5):200-206.
11. Meyer V, Wu B, Ram AF. *Aspergillus* as a multi-purpose cell factory: current status and perspectives. *Biotechnol Lett* 2011;33(3):469-476.
12. Moore D, Chiu SW. Fungal products as food. In: Pointing S, Hyde K (eds). *Bio-exploitation of filamentous fungi*. Hong Kong: Fungal Diversity Press; 2001, 223-251.
13. Jayani R, Saxena S, Gupta R. Microbial pectinolytic enzymes: A review. *Process Biochem* 2005;40:2931-2944.
14. Lee K, Lee S, Lee B. *Aspergillus oryzae* as probiotic in poultry-A review. *Int J Poult Sci* 2006;5(1):1-3.
15. Fleissner A, Dersch P. Expression and export: recombinant protein production systems for *Aspergillus*. *Appl Microbiol Biotechnol* 2010;87(4):1255-1270.
16. Aleksenko AY, Clutterbuck AJ. Recombinational stability of replicating plasmids in *Aspergillus nidulans* during transformation, vegetative growth and sexual reproduction. *Curr Genet* 1995;28(1):87-93.
17. Aleksenko A, Clutterbuck AJ. Autonomous plasmid replication in *Aspergillus nidulans*: AMA1 and MATE elements. *Fungal Genet Biol* 1997;21(3):373-387.
18. Aleksenko A, Nikolaev I, Vinetski Y, Clutterbuck AJ. Gene expression from replicating plasmids in *Aspergillus nidulans*. *Mol Gen Genet* 1996;253(1-2):242-246.
19. Bos CJ, Debets AJ, Swart K, Huybers A, Kobus G, Slakhorst SM. Genetic analysis and the construction of master strains for assignment of genes to six linkage groups in *Aspergillus niger*. *Curr Genet* 1988;14(5):437-443.
20. Vogel H. A convenient growth medium for *Neurospora* (medium N). *Microb Genet Bull* 1956; 13:42-44.
21. van Hartingsveldt W, Mattern IE, van Zeijl CM, Pouwels PH, van den Hondel CA. Development of a homologous transformation system for *Aspergillus niger* based on the *pyrG* gene. *Mol Gen Genet* 1987;206(1):71-75.
22. Macreadie IG, Vaughan PR, Chapman AJ, McKern NM, Jagadish MN, Heine HG, et al. Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast. *Vaccine* 1990;8(6):549-552.
23. Sharma R, Katoch M, Srivastava P, Qazi GN. Approaches for refining heterologous protein production in filamentous fungi. *World J Microbiol Biotechnol* 2009;25(12):2083-2094.
24. Storms R, Zheng Y, Li H, Sillaots S, Martinez-Perez A, Tsang A. Plasmid vectors for protein production, gene expression and molecular manipulations in *Aspergillus niger*. *Plasmid* 2005;53(3):191-204.

25. Gouka RJ, Punt PJ, Hessing JG, van den Hondel CA. Analysis of heterologous protein production in defined recombinant *Aspergillus awamori* strains. *Appl Environ Microbiol* 1996;62(6):1951-1957.
26. Koda A, Bogaki T, Minetoki T, Hirotsume M. High expression of a synthetic gene encoding potato alpha-glucan phosphorylase in *Aspergillus niger*. *J Biosci Bioeng* 2005;100(5):531-537.
27. Prathumpai W, Flitter SJ, McIntyre M, Nielsen J. Lipase production by recombinant strains of *Aspergillus niger* expressing a lipase-encoding gene from *Thermomyces lanuginosus*. *Appl Microbiol Biotechnol* 2004;65(6):714-719.
28. Heine HG, Hyatt AD, Boyle DB. Modification of infectious bursal disease virus antigen VP2 for cell surface location fails to enhance immunogenicity. *Virus Res* 1994;32(3):313-328.
29. Azad AA, Macreadie IGT, Mckern NML, Vaughan PRR, Jagadish MNGP, Fahey KJT, inventors; Production of IBDV VP2 in highly immunogenic form. Australia patent AU PCT/AU 1990/000224. 1997 May 29.
30. Aziz MA, Midha S, Waheed SM, Bhatnagar R. Oral vaccines: new needs, new possibilities. *Bioessays* 2007;29(6):591-604.
31. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. *BMC Biol* 2010;8:129.
32. Solis de los Santos F, Farnell MB, Tellez G, Balog JM, Anthony NB, Torres-Rodriguez A, et al. Effect of prebiotic on gut development and ascites incidence of broilers reared in a hypoxic environment. *Poult Sci* 2005;84(7):1092-1100.
33. Londero A, Menconi A, Reginatto AR, Bacocina AI, Wolfenden A, Shivaramaiah S, et al. Effect of an aspergillus meal prebiotic on salmonella infection in turkeys and broiler chickens. *Int J Poult Sci* 2011;10(12):946-951.